PF 4523655

Drug Profile

PF 4523655

Alternative Names: PF-04523655; PF-4523655; PF-655; PFE-4523655; REDD-14-NP; RTP 801i-14; RTP-801i

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Quark Pharmaceuticals
  • Class Eye disorder therapies; Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic macular oedema; Wet age-related macular degeneration

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 17 Jun 2015 Phase-II development is ongoing for diabetic macular oedema and wet age-related macular degeneration USA, European Union, Asia, Latin America and the Middle East
  • 02 May 2012 Quark and Pfizer amend their licensing agreement for PF 4523655 to allow Quark to conduct a phase IIa trial of the product in patients with open-angle glaucoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top